Interaction Checker

Trastuzumab : interactions médicamenteuses

Trastuzumab (Herceptin, Ogivri, Kanjinti) présente 75 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 4 de niveau majeur, 48 de niveau modéré, 23 de niveau mineur et 0 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions majeures (4)

  • CyclophosphamideimmunosuppresseurMajeure

    AC Anthracycline (doxorubicin) and cyclophosphamide. → Paclitaxel+Trastuzumab 3.2% (64/2000) Includes 1 patient with fatal cardiomyopathy and 1 patient with sudden death without documented etiology. (notice Trastuzumab, Mises en garde et précautions)

  • DoxorubicineMajeure

    AC Anthracycline (doxorubicin) and cyclophosphamide. → Paclitaxel+Trastuzumab 3.2% (64/2000) Includes 1 patient with fatal cardiomyopathy and 1 patient with sudden death without documented etiology. (notice Trastuzumab, Mises en garde et précautions)

  • Itraconazoleantifongique azoléMajeure

    Axitinib Bosutinib Cabazitaxel Cabozantinib Ceritinib Cobimetinib Crizotinib Dabrafenib Dasatinib Docetaxel Ibrutinib Lapatinib Nilotinib Olaparib Pazopanib Sunitinib Trabectedin Trastuzumab-­emtansine Vinca alkaloids Not recommended during and 2 weeks after TOLSURA treatment. (notice Itraconazole, Interactions médicamenteuses)

  • PaclitaxelMajeure

    AC Anthracycline (doxorubicin) and cyclophosphamide. → Paclitaxel+Trastuzumab 3.2% (64/2000) Includes 1 patient with fatal cardiomyopathy and 1 patient with sudden death without documented etiology. (notice Trastuzumab, Mises en garde et précautions)

Interactions modérées (48)

  • AclidiniumanticholinergiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • AdrénalinesympathomimétiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • AminophyllineméthylxanthineModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Arformotérolagoniste bêta-adrénergiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Articaïne et adrénalineanesthésique localModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Azélastine et fluticasoneantihistaminiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • BéclométasonecorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • BétaméthasonecorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • BudésonidecorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Budésonide et formotérolcorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Bupivacaïne et adrénalineanesthésique localModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • CarboplatineModérée

    In BCIRG006, a total of 2.9% (31/1056) of patients in the TCH (docetaxel, carboplatin, trastuzumab) arm (1.5% during the chemotherapy phase and 1.4% during the monotherapy phase) and 5.7% (61/1068) of patients in the AC-TH arm (1.5% during the chemotherapy phase and 4.2% during the monotherapy phase) discontinued trastuzumab due to cardiac toxicity. (notice Trastuzumab, Mises en garde et précautions)

  • CiclésonidecorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • ClobétasolcorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • DéflazacortcorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • DésonidecorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • DexaméthasonecorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • DiphénhydramineantihistaminiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • DocétaxelModérée

    In BCIRG006, a total of 2.9% (31/1056) of patients in the TCH (docetaxel, carboplatin, trastuzumab) arm (1.5% during the chemotherapy phase and 1.4% during the monotherapy phase) and 5.7% (61/1068) of patients in the AC-TH arm (1.5% during the chemotherapy phase and 4.2% during the monotherapy phase) discontinued trastuzumab due to cardiac toxicity. (notice Trastuzumab, Mises en garde et précautions)

  • FludrocortisonecorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • FlunisolidecorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • FluocinonidecorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • FluticasonecorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Fluticasone et salmétérolcorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Formotérolagoniste bêta-adrénergiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • HalobétasolcorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • HydrocortisonecorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • IpratropiumanticholinergiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Ipratropium et salbutamolanticholinergiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Isoprénalineagoniste bêta-adrénergiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Lévosalbutamolagoniste bêta-adrénergiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Lidocaïne et adrénalineanesthésique localModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • MéthylprednisolonecorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Mirabégronagoniste bêta-adrénergiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • MométasonecorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Olopatadine et mométasoneantihistaminiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • PrednisolonecorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • PrednisonecorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Prilocaïne et adrénalineanesthésique localModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Salbutamolagoniste bêta-adrénergiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Salmétérolagoniste bêta-adrénergiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Terbutalineagoniste bêta-adrénergiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • ThéophyllineméthylxanthineModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • TiotropiumanticholinergiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • TriamcinolonecorticoïdeModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • UméclidiniumanticholinergiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Uméclidinium et vilantérolanticholinergiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

  • Vibégronagoniste bêta-adrénergiqueModérée

    Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

Mentions mineures (23)

  • AzélastineantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • Bromphéniramine, pseudoéphédrine et dextrométhorphaneantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • CarbinoxamineantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • CétirizineantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • ChlorphénamineantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • ClémastineantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • CyproheptadineantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • DesloratadineantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • DexchlorphéniramineantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • DimenhydrinateantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • DoxylamineantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • Doxylamine et pyridoxineantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • FexofénadineantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • Hydrocodone et chlorphénamineopioïdeMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • HydroxyzineantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • LévocétirizineantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • LoratadineantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • MéclozineantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • OlopatadineantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • Palbociclibinhibiteur du CYP3A4Mineure

    Grade ≥3 neutropenia was reported in 61% of patients receiving IBRANCE in combination with trastuzumab, with or without pertuzumab, and endocrine therapy. (notice Palbociclib, Mises en garde et précautions)

  • ProméthazineantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • Prométhazine et codéineopioïdeMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

  • Prométhazine et dextrométhorphaneantihistaminiqueMineure

    Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (notice Trastuzumab, Mises en garde et précautions)

Vérifiez Trastuzumab avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.